<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593371</url>
  </required_header>
  <id_info>
    <org_study_id>90-D-130-655</org_study_id>
    <nct_id>NCT01593371</nct_id>
  </id_info>
  <brief_title>Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients</brief_title>
  <official_title>Comparing Effects of Metformin and Pioglitazone on Regulation of Serum Adipokines in Newly Diagnosed Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral hypoglycemic agents encompass the mainstay of treatment in the majority of patients with
      type 2 diabetes. Thiazolidinediones (such a pioglitazone) and Biguanides (such as metformin),
      are two major groups of hypoglycemic medications that while function via different pathways,
      are both effective in short- and long-term glycemic control . These medications diminish or
      at least delay long term micro- and macrovascular complications associated with prolonged
      insulin resistance although at different rates. The mechanisms by which this aim is achieved,
      nevertheless, remains largely unclear. With adipokines playing a key role in development of
      both insulin resistance and atherosclerosis, oral hypoglycemic agents might regulate these
      substances by direct and indirect routes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentrations of omentin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum concentrations of adipose tissue derived cytokine omentin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum concentrations of leptin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum concentrations of adipose tissue derived cytokine leptin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving fixed dose metformin 1000 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving fixed dose pioglitazone 30 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed type 2 diabetes patients based on American Diabetes Association
             criteria (2011) for diagnosis of diabetes

        Exclusion Criteria:

          -  previous intake of oral hypoglycemic agents for treatment of diabetes or other
             hyperglycemia associated conditions

          -  intake of glucocorticoids in the past one year

          -  major illnesses of heart, lung, kidney, and liver.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alireza Esteghamati, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <zip>13145-784</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Alireza Esteghamati</investigator_full_name>
    <investigator_title>Professor Alireza Esteghamati</investigator_title>
  </responsible_party>
  <keyword>Adipokines</keyword>
  <keyword>leptin</keyword>
  <keyword>chemerin</keyword>
  <keyword>omentin</keyword>
  <keyword>metformin</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

